Ocedurenone, formerly known as KBP-5074,[1] is a nonsteroidal, selective mineralocorticoid receptor antagonist that is being developed to treat hypertension in patients with chronic kidney disease with less risk of hyperkalemia than existing treatments.

[2][3] In 2023, KPB Biosciences entered into talks to sell the drug to Novo Nordisk for USD$1.3 billion.

It is a small molecule drug administered orally and is in a Phase III trial that is scheduled to complete in 2024.

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.